

Patients with chronic periodontitis present increased risk for primary Sjögren syndrome: a nationwide population-based cohort study

Tai-Chen Lin^{1,2,*}, Chien-Fang Tseng^{2,*}, Yu-Hsun Wang³,
Hui-Chieh Yu² and Yu-Chao Chang^{1,2}

¹ Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan

² School of Dentistry, Chung Shan Medical University, Taichung, Taiwan

³ Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan

* These authors contributed equally to this work.

ABSTRACT

Many reports have mentioned the association between chronic periodontitis (CP) and primary Sjögren syndrome (pSS). However, no cohort study has been performed for the risk of pSS in patients with CP. In this study, we evaluated the risk of pSS from CP exposure in a nationwide population-based cohort study in Taiwan. We studied the claims data of Taiwanese population from 2001 to 2012. We identified 76,765 patients with CP from the National Health Insurance Database in Taiwan. We also selected 76,765 controls that were randomly frequency matched by age, sex, and index year from the general population. We analyzed the risk of pSS by using Cox proportional hazards regression models including sex, age, and comorbidities. In this study, 76,765 patients with CP (mean age: 40.8 years) and 76,765 controls (mean age: 41.0 years) were followed-up for 8.54 and 8.49 years, respectively. A total of 869 cases of pSS were identified in CP cohort and 483 cases in non-CP cohort. Multivariate Cox regression analysis indicated that the incidence rate of pSS was significantly higher in CP cohort than those who in non-CP cohort (adjusted HR: 1.79, 95% CI [1.60–2.00]). Taken together, this nationwide retrospective cohort study demonstrated that the risk of pSS was significantly higher in patients with CP than in the general population. The association between CP and pSS was significant in the female group.

Submitted 29 March 2018

Accepted 6 June 2018

Published 20 June 2018

Corresponding author

Yu-Chao Chang, cyc@csmu.edu.tw

Academic editor

Praveen Arany

Additional Information and
Declarations can be found on
page 8

DOI 10.7717/peerj.5109

© Copyright

2018 Lin et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Dentistry, Epidemiology, Immunology, Public Health, Rheumatology

Keywords Chronic periodontitis, Primary Sjögren syndrome, Nationwide population, Cohort study, Taiwan

INTRODUCTION

Chronic periodontitis (CP) is the most common periodontal disease which is related to the chronic accumulation of bacterial biofilm leading to host-mediated slowly progressive destruction of periodontium. CP is the primary risk factor for tooth loss in adults (*Agerholm, 2001*). Recently, studies have also shown that CP is a risk factor for many systemic diseases including cardiovascular disease (*Dietrich et al., 2013*), diabetes mellitus (*Borgnakke et al., 2013*), and rheumatoid arthritis (*Tang et al., 2017*).

The possible mechanisms involving the modulations of inflammatory pathway and systemic immunity are associated with a bacterial challenge and represent a portal of entry for periodontal pathogens, bacterial endotoxins, and pro-inflammatory cytokines (Ebersole *et al.*, 2017).

Primary Sjögren's syndrome (pSS) is a systemic disease characterized by chronic autoimmune reaction with progressive lymphocytic infiltration of salivary and lacrimal glands leading to dry eyes and dry mouth (Ramos-Casals & Font, 2005; Ramos-Casals *et al.*, 2012). Secondary Sjögren's syndrome occurs in the presence of other autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus. The prevalence of pSS is higher among female than among in male (Qin *et al.*, 2015). The incidence rate of pSS was 10.6 per 100,000 person-years in Taiwan (Yu *et al.*, 2013).

The increasing prevalence of CP was found in pSS patients with compromised salivary flow and consequent higher dental plaque index (Boutsi *et al.*, 2000; Pers *et al.*, 2005). Contrarily, Lugonja *et al.* (2016) reported no increase in the prevalence of CP in pSS patients. However, no cohort study has been conducted to evaluate the risk of pSS in patients with CP in a large population. Therefore, the association between CP and pSS still needs further investigation.

The Taiwan National Health Insurance (NHI) program is a mandatory health insurance program that began in 1995 and has provided health care up to 99.9% population in 2014 (National Health Insurance Administration, 2014). The National Health Insurance Research Database (NHIRD) was established in 1997 for scientific and research studies. This database has been used for many longitudinal epidemiological studies for assessment the burden of periodontitis (Chen, Wu & Chang, 2017a, 2017b; Yu *et al.*, 2017, 2018; Su *et al.*, 2017). Therefore, this study assessed the risk of pSS in a large, nationally representative, population-based cohort of patients with CP in Taiwan.

METHODS

Data source

The Longitudinal Health Insurance Database 2010 (LHID2010) was used for this cohort study. This database provides scrambled patient identification number, date of birth, sex, diagnostic codes in the format of the International Classification of Disease, Revision 9, Clinical Modification (ICD-9-CM) code, and the date of visit to medical institutes as described previously (Chen, Wu & Chang, 2017b; Su *et al.*, 2017).

Exposure of CP

After being approved by the Chung Shan Medical University Hospital institutional review board (CS2-15071), we identified the ambulatory patients for dental visit with newly diagnosed CP (ICD-9-CM code: 523.4) from 2001 to 2012 as a newly onset CP cohort. The first-time CP diagnosis served as the index date. To ensure the accuracy of CP diagnosis, only patients with at least three outpatient service claims were recruited.

Subjects without periodontitis were randomly selected from the data set and identified as periodontally healthy controls. The comparison group included the participations who were never diagnosed with CP from 2001 to 2012. In order to reduce the confounding

bias, we used propensity score matching to select controls. Propensity score of participants which predicted the probability of CP exposure for participants was estimated by logistic regression modeling. In addition to traditional confounding factors, chronic insomnia (ICD-9-CM, code 780.52) was first included to assess as recently reported as an important risk factor of pSS (*Kok et al., 2016*). The predictors involved birth year, sex, and co-morbidities at baseline. The 1:1 matched comparisons were selected with the same propensity score in as exposure subject. Patients diagnosed as having periodontitis before 2001 were excluded.

Primary Sjögren syndrome event

The diagnosis and code (ICD-9-CM 710.2) of pSS were according to the European classification criteria for Sjögren syndrome in 2002 (*Qin et al., 2015*). All participants were followed-up from index date to the date of the primary outcome, withdrawal from the NHI programme or the end of 2013, whichever came first. In addition, we excluded patients with comorbidities such as systemic lupus erythematosus (ICD-9-CM 710.0), rheumatoid arthritis (ICD-9-CM 714), ankylosing spondylitis (ICD-9-CM 720.0), polymyositis (ICD-9-CM 710.4), and dermatomyositis (ICD-9-CM 710.3) to limit our study sample as pSS during the observation period.

Statistical analysis

The Student's *t* test and Chi-square test were used to analyze the difference of continuous and categorical variables, respectively. The Cox proportional hazard models were applied to estimate the hazard ratios of CP. All statistical analyses were performed with the SPSS version 18 (SPSS, Chicago, IL, USA), and the significant level was 0.05.

RESULTS

As shown in [Table 1](#), we enrolled 76,765 patients with CP and 76,765 subjects without CP. The two groups had similar mean age and sex ratio because of the frequency matching for age and sex. There were also no income and urbanization variation ($p > 0.05$). The percentage of comorbidities hypertension, hyperlipidemia, chronic insomnia, and CCI showed no significant differences between patients with CP and the healthy controls ($p > 0.05$).

The newly diagnosed pSS patients were 869 in CP group and 483 individuals in non-CP group. The incidence density rates of pSS in non-CP group was only 0.7 per 1,000 person-years ([Table 2](#)), but the incidence density rates was about 1.86-fold higher in CP group than in non-CP group (1.3 per 1,000 person-years). [Figure 1](#) shows the cumulative curve of the pSS incidence and reveals that the curve of CP patients was significantly higher than the curve of control subjects (log rank test, $p < 0.001$). After adjustment of sex, age, monthly income, urbanization, and comorbidities, CP patients showed a 1.79-fold increased risk of pSS compared with non-CP patients (HR 1.79, 95% CI [1.60–2.00]). However, there was no significant risk for pSS with income, urbanization, and hypertension in the adjusted model.

Table 1 Demographic data.

	Chronic periodontitis (N = 76,765)		Control (N = 76,765)		p-value
	n	%	n	%	
Age					0.991
<20	8,271	10.8	8,252	10.7	
20–39	29,359	38.2	29,333	38.2	
40–64	32,665	42.6	32,725	42.6	
≥65	6,470	8.4	6,455	8.4	
Mean ± SD	40.8 ± 16.3		41.0 ± 16.2		0.011*
Gender					0.613
Female	40,525	52.8	40,624	52.9	
Male	36,240	47.2	36,141	47.1	
Monthly income					0.772
<NT \$20,000	37,636	49.0	37,609	49.0	
NT \$20,000–NT \$40,000	21,188	27.6	21,301	27.7	
>NT \$40,000	17,941	23.4	17,855	23.3	
Urbanization					0.857
Urban	51,719	67.4	51,748	67.4	
Suburban	20,704	27.0	20,725	27.0	
Rural	4,342	5.7	4,292	5.6	
Hypertension	9,421	12.3	9,472	12.3	0.692
Hyperlipidemia	5,652	7.4	5,670	7.4	0.860
Chronic insomnia	1,755	22.9	17,495	22.8	0.738
CCI [†]					0.819
0	58,417	76.1	58,342	76.0	
1	15,107	19.7	15,136	19.7	
≥2	3,241	4.2	3,287	4.3	

Notes:

Demographic data of matched study cohorts.

The Student's *t* test and Chi-squared test were used to test the difference of continuous and categorical variables, respectively.[†] Charlson comorbidity index.* *p* < 0.05.

In the stratified follow-up duration analysis, the risk of pSS was significantly higher by 1.87, 1.66, and 1.65 fold during the first seven years, seven to 10 years, the subsequent 10 years, respectively, in CP cohort compared with in non-CP cohort (Table 3).

The mean follow-up duration and time to pSS between the CP and the non-CP group was shown in Table 4. The mean follow-up duration of pSS was 8.54 years and 8.49 years for the CP and non-CP group, respectively. The mean time to pSS was 4.75 and 4.98 years for the CP and non-CP group, respectively.

DISCUSSION

This is the first nationwide population-based cohort study to evaluate the association between CP exposure and pSS risk by using a matched cohort and long term follow-up period. We found a higher risk of pSS in patients with CP exposure than those who never

Table 2 Risk factors.

	No. of event	Observed person-years	ID	Crude HR	95% C.I.		Adjusted HR [†]	95% CI	
					Lower	Upper		Lower	Upper
Chronic periodontitis									
No	483	651,552	0.7	1			1		
Yes	869	655,566	1.3	1.79**	1.60	2.00	1.79**	1.60	2.00
Age									
<20	53	135,583	0.4	1			1		
20–39	339	518,847	0.7	1.67**	1.25	2.23	1.56**	1.16	2.10
40–64	747	549,571	1.4	3.48**	2.63	4.60	2.82**	2.11	3.78
≥65	213	103,117	2.1	5.28**	3.91	7.14	3.67**	2.66	5.05
Gender									
Male	352	615,103	0.6	1			1		
Female	1,000	692,015	1.4	2.52**	2.24	2.85	2.55**	2.25	2.88
Monthly income									
<NT \$20,000	677	639,530	1.1	1			1		
NT \$20,000–NT \$40,000	384	359,006	1.1	1.01	0.89	1.15	0.94	0.82	1.07
>NT \$40,000	291	308,582	0.9	0.89	0.78	1.02	1.02	0.88	1.18
Urbanization									
Urban	903	879,933	1.0	1			1		
Suburban	381	354,024	1.1	1.05	0.93	1.18	1.07	0.94	1.20
Rural	68	73,161	0.9	0.91	0.71	1.16	0.86	0.67	1.11
Hypertension	266	149,842	1.8	1.89**	1.65	2.16	0.99	0.84	1.15
Hyperlipidemia	176	86,980	2.0	2.10**	1.79	2.46	1.24*	1.04	1.47
Chronic insomnia	634	304,042	2.1	2.91**	2.62	3.24	2.08**	1.86	2.32
CCI [†]									
0	839	999,322	0.8	1			1		
1	421	256,471	1.6	1.95**	1.74	2.20	1.38**	1.21	1.56
≥2	92	51,325	1.8	2.14**	1.72	2.65	1.30*	1.03	1.62

Notes:

Risk factor analysis of primary Sjögren's syndrome development.

[†] Charlson comorbidity index; ID: Incidence density, per 1,000 person-years.

^{††} Adjusted for age, gender, monthly income, urbanization, hypertension, hyperlipidemia, chronic insomnia, and Charlson comorbidity index.

* $p < 0.05$.

** $p < 0.01$.

received a diagnosis of CP. In addition, the association between CP and pSS was significant in the female group.

Recently, *Lugonja et al. (2016)* reported a lack of statistical significance in pSS patients with moderate/severe periodontitis. However, this study had limited sample sizes only in one hospital, making it difficult to generalize the results. Consistent with our findings, patients with pSS increased the utilization of dental services at least eight years before the definitive diagnosis with an increase in periodontal problems (*Lu et al., 2014*). Recently, a longitudinal prospective study demonstrated that non-surgical periodontal treatment could significantly improve salivary flow in pSS patients (*Ambrósio et al., 2017*). Taken together, these studies implied the positive association between periodontitis and pSS.




Figure 1 KM plot.

Full-size DOI: 10.7717/peerj.5109/fig-1

Table 3 Hazard ratios.

Follow-up duration (years)	Chronic periodontitis		Control		HR [†]	95% CI	
	No. of event	ID	No. of event	ID		Lower	Upper
<7 yrs	649	5.5	347	2.9	1.87**	1.64	2.13
7–10 yrs	163	0.9	102	0.5	1.66**	1.30	2.13
≥ 10 yrs	57	0.2	34	0.1	1.65*	1.08	2.53

Notes:

Hazard ratios of primary Sjögren's syndrome stratified by follow-up duration.

ID: Incidence density, per 1,000 person-years.

[†] Adjusted for age, gender, monthly income, urbanization, hypertension, hyperlipidemia, chronic insomnia, and Charlson comorbidity index.

* $p < 0.05$.

** $p < 0.01$.

Our study first evaluated the risk of pSS stratified by follow-up years in multivariable Cox proportional hazard regression. The risk of pSS was significantly higher in the CP group as compared to the periodontal healthy control group. Taken together, these findings indicate that the regular oral check-up for periodontal condition may be necessary for individuals with pSS.

Table 4 Time to event.

	Chronic periodontitis (<i>N</i> = 76,765)	Control (<i>N</i> = 76,765)	<i>p</i> -value
Follow-up duration (years)	8.54 ± 3.08	8.49 ± 3.10	0.001**
Time to event (years), <i>N</i> = 1,352	4.75 ± 3.06	4.98 ± 3.03	0.190

Notes:

Track time of CP and control cohort.

The Student's *t* test was used to test the difference of continuous variables.

** *p* < 0.01.

We hypothesized that the possible mechanism of the increased risk of CP in pSS patients may be associated with immune-inflammation and periodontal pathogens. Periodontitis is characterized by a dysregulation of the immune-inflammatory response to periodontal pathogens. Patients with pSS exhibited significantly elevated antibody levels to some predominate periodontal pathogens as compared with systemically healthy individuals (Celenligil *et al.*, 1998) or periodontitis (Lugonja *et al.*, 2016). It is not clear how microbiome analysis will provide meaningful data related to autoantibody levels or inflammation in general. However, overexpression of several inflammatory cytokines has been demonstrated both in pSS and CP (Barone & Colafrancesco, 2016; Darveau, 2010). Therefore, just by having CP may lead to the development of pSS without a genetic predisposition.

The strength of this study was the use of a nationwide database composed of general population in Taiwan and a matched control group that may have avoided the selection bias between CP and pSS. We adopted a frequency-matched cohort study design by using the patients with CP and adequate adjusted for sex, age, and index year. In addition, the cohort study design could confer a higher level of evidence to suggest a causal relationship rather than the case control design.

Some potential limitations should be noted before the interpretation of data. First, in Taiwan, Sjögren syndrome is recognized as a catastrophic illness covered under the NHI scheme. Patients with minor manifestations of this disease might not have applied for a catastrophic illness certificate. In this study, the ICD codes from the LHID2010 claim database might be affected by the diagnostic accuracy of this database because of the lack of data on the severity of pSS, laboratory results, and the indications for medication use. However, the regular check of the quality of claims data from all medical institutions by the NHI Administration has improved the coding accuracy and hence minimized bias due to misclassification. In addition, there are 23 medical specialties approved by government of Taiwan. Further, patients suspected of having pSS will be referred to a Rheumatology appointment for a definitive diagnosis and will receive further treatment within the NHI system.

Second, the severity of CP as a risk factor for developing pSS could not be explored. The collected data regarding the diagnosis of CP based on ICD-9 codes recorded in the NHIRD may not truly indicate the severity of periodontitis. However, to ensure the criteria of indication and quality of treatment, the NHI has established the strict guideline that only board-registered dentists can execute the dental treatment according

to the strictly NHI therapeutic guidelines. Therefore, the periodontal diagnosis could reach the measurement reproducibility in Taiwan.

Third, due to this is a register-based study, the unrecognized periodontitis which did not have dental medical claims might be included in the healthy controls through the study design. By using the propensity score matching could reduce the selection bias and avoid the confounding variates.

Forth, periodontitis prevalence appears to be high even in areas with adequate access to oral health care. Therefore, perhaps misclassification bias may influence the risk estimate in this study leading to under-estimated the odds ratio of pSS for CP exposure. Our previous report has indicated that the prevalence rate of periodontal disease was estimated by lowering to 11.5% to 19.59% from NHIRD (*Yu et al., 2017*). Taken together, patients with CP are with increased risk for pSS in Taiwan. Finally, information on individual behaviors, such as smoking and alcohol consumption are unavailable from the database. Nevertheless, possible effects due to confounding bias from above factors might be minimized after adjusting for age, sex, income, and urbanization.

CONCLUSIONS

The findings of this nationwide, population-based cohort study revealed a significant association between CP exposure and pSS risk. However, further prospective clinical studies on the relationship between CP and pSS are warranted.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Tai-Chen Lin conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the paper, approved the final draft.
- Chien-Fang Tseng conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the paper, approved the final draft.
- Yu-Hsun Wang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, approved the final draft.
- Hui-Chieh Yu contributed reagents/materials/analysis tools, prepared figures and/or tables, approved the final draft.
- Yu-Chao Chang conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Chung Shan Medical University Hospital institutional review board approved this study (CS2-15071).

Data Availability

The following information was supplied regarding data availability:

The data are provided in a [Supplemental File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.5109#supplemental-information>.

REFERENCES

- Agerholm D. 2001.** Reasons for extraction by dental practitioners in England and Wales: a comparison with 1986 and variations between regions. *Journal of Dentistry* **29**(4):237–241 DOI [10.1016/s0300-5712\(01\)00013-6](https://doi.org/10.1016/s0300-5712(01)00013-6).
- Ambrósio LM, Rovai ES, França BN, Balzarini DA, Abreu IS, Lopes SB, Nunes TB, Lourenço SV, Pasoto SG, Saraiva L, Holzhausen M, Universidade de São Paulo, Brazil. 2017.** Effects of periodontal treatment on primary Sjögren's syndrome symptoms. *Brazilian Oral Research* **31**:e8.
- Barone F, Colafrancesco S. 2016.** Sjögren's syndrome: from pathogenesis to novel therapeutic targets. *Clinical and Experimental Rheumatology* **34**:S58–S62.
- Borgnakke WS, Ylostalo PV, Taylor GW, Genco RJ. 2013.** Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. *Journal of Clinical Periodontology* **40**:S135–S152 DOI [10.1111/jcpe.12080](https://doi.org/10.1111/jcpe.12080).
- Boutsi EA, Paikos S, Dafni UG, Moutsopoulos HM, Skopouli FN. 2000.** Dental and periodontal status of Sjögren's syndrome. *Journal of Clinical Periodontology* **27**(4):231–235 DOI [10.1034/j.1600-051x.2000.027004231.x](https://doi.org/10.1034/j.1600-051x.2000.027004231.x).
- Celenligil H, Eratalay K, Kansu E, Ebersole JL. 1998.** Periodontal status and serum antibody responses to oral microorganisms in Sjögren's Syndrome. *Journal of Periodontology* **69**(5):571–577 DOI [10.1902/jop.1998.69.5.571](https://doi.org/10.1902/jop.1998.69.5.571).
- Chen CK, Wu YT, Chang YC. 2017a.** Association between chronic periodontitis and the risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study. *Alzheimer's Research & Therapy* **9**(1):56 DOI [10.1186/s13195-017-0282-6](https://doi.org/10.1186/s13195-017-0282-6).
- Chen CK, Wu YT, Chang YC. 2017b.** Periodontal inflammatory disease is associated with the risk of Parkinson's disease: a population-based retrospective matched-cohort study. *PeerJ* **5**:e3647 DOI [10.7717/peerj.3647](https://doi.org/10.7717/peerj.3647).
- Darveau RP. 2010.** Periodontitis: a polymicrobial disruption of host homeostasis. *Nature Reviews Microbiology* **8**(7):481–490 DOI [10.1038/nrmicro2337](https://doi.org/10.1038/nrmicro2337).
- Dietrich T, Sharma P, Walter C, Weston P, Beck J. 2013.** The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease. *Journal of Clinical Periodontology* **40**:S70–S84 DOI [10.1111/jcpe.12062](https://doi.org/10.1111/jcpe.12062).
- Ebersole JL, Dawson D 3rd, Emecen-Huja P, Nagarajan R, Howard K, Grady ME, Thompson K, Peyyala R, Al-Attar A, Lethbridge K, Kirakodu S, Gonzalez OA. 2017.** The periodontal war: microbes and immunity. *Periodontology 2000* **75**(1):52–115 DOI [10.1111/prd.12222](https://doi.org/10.1111/prd.12222).

- Kok VC, Horng JT, Hung GD, Xu JL, Hung TW, Chen YC, Chen CL. 2016.** Risk of autoimmune disease in adults with chronic insomnia requiring sleep-inducing pills: a population-based longitudinal study. *Journal of General Internal Medicine* 31(9):1019–1026 DOI 10.1007/s11606-016-3717-z.
- Lu MC, Jheng CH, Tsai TY, Koo M, Lai NS. 2014.** Increased dental visits in patients prior to diagnosis of primary Sjögren's syndrome: a population-based study in Taiwan. *Rheumatology International* 34(11):1555–1561 DOI 10.1007/s00296-014-3003-5.
- Lugonja B, Yeo L, Milward MR, Smith D, Dietrich T, Chapple IL, Rauz S, Williams GP, Barone F, de Pablo P, Buckley C, Hamburger J, Richards A, Poveda-Gallego A, Scheel-Toellner D, Bowman SJ. 2016.** Periodontitis prevalence and serum antibody reactivity to periodontal bacteria in primary Sjögren's syndrome: a pilot study. *Journal of Clinical Periodontology* 43(11):26–33 DOI 10.1111/jcpe.12485.
- National Health Insurance Administration. 2014.** *National Health Insurance Annual Report 2014–2015*. Taiwan, R.O.C: Ministry of Health and Welfare.
- Pers JO, D'Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. 2005.** Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome? *Arthritis & Rheumatism* 52(8):2411–2414 DOI 10.1002/art.21205.
- Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. 2015.** Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. *Annals of the Rheumatic Diseases* 74(11):1983–1989 DOI 10.1136/annrheumdis-2014-205375.
- Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. 2012.** Primary Sjogren syndrome. *BMJ* 344:e3821 DOI 10.1136/bmj.e3821.
- Ramos-Casals M, Font J. 2005.** Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts. *Rheumatology* 44(11):1354–1367 DOI 10.1093/rheumatology/keh714.
- Su NY, Huang JY, Hu CJ, Yu HC, Chang YC. 2017.** Increased risk of periodontitis in patients with psoriatic disease: a nationwide population-based retrospective cohort study. *PeerJ* 5:e4064 DOI 10.7717/peerj.4064.
- Tang Q, Fu H, Qin B, Hu Z, Liu Y, Liang Y, Zhou L, Yang Z, Zhong R. 2017.** A Possible link between rheumatoid arthritis and periodontitis: a systematic review and meta-analysis. *International Journal of Periodontics and Restorative Dentistry* 37(1):79–86 DOI 10.11607/prd.2656.
- Yu HC, Chen TP, Wei CY, Chang YC. 2018.** Association between peptic ulcer disease and periodontitis: a nationwide population-based case-control study in Taiwan. *International Journal of Environmental Research and Public Health* 15(5):912 DOI 10.3390/ijerph15050912.
- Yu KH, See LC, Kuo CF, Chou IJ, Chou MJ. 2013.** Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. *Arthritis Care & Research* 65(2):244–250 DOI 10.1002/acr.21820.
- Yu HC, Su NY, Huang JY, Lee SS, Chang YC. 2017.** Trends in the prevalence of periodontitis in Taiwan from 1997 to 2013: a nationwide population-based retrospective study. *Medicine* 96(45):e8585 DOI 10.1097/md.00000000000008585.